Shanghai Labway Clinical Laboratory Co Ltd
SZSE:301060
Shanghai Labway Clinical Laboratory Co Ltd
SZSE:301060
Price:
10.2 CNY
-0.49%
Market Closed
Updated:
May 4, 2024
Income Statement
Earnings Waterfall
Shanghai Labway Clinical Laboratory Co Ltd
Shanghai Labway Clinical Laboratory Co Ltd
|
Revenue
|
2.4B
CNY
|
|
Cost of Revenue
|
-1.6B
CNY
|
|
Gross Profit
|
735.4m
CNY
|
|
Operating Expenses
|
-666m
CNY
|
|
Operating Income
|
69.4m
CNY
|
|
Other Expenses
|
-57.3m
CNY
|
|
Net Income
|
12.1m
CNY
|
Income Statement
Shanghai Labway Clinical Laboratory Co Ltd
Shanghai Labway Clinical Laboratory Co Ltd
Currency: CNY
| Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||
| Revenue |
1 595
N/A
|
1 509
-5%
|
1 649
+9%
|
1 778
+8%
|
2 250
+27%
|
3 068
+36%
|
3 613
+18%
|
4 199
+16%
|
3 784
-10%
|
2 977
-21%
|
2 360
-21%
|
|
| Gross Profit | ||||||||||||
| Cost of Revenue |
(1 062)
|
(987)
|
(1 041)
|
(1 105)
|
(1 316)
|
(1 723)
|
(2 078)
|
(2 420)
|
(2 276)
|
(1 940)
|
(1 625)
|
|
| Gross Profit |
532
N/A
|
522
-2%
|
608
+17%
|
673
+11%
|
934
+39%
|
1 345
+44%
|
1 535
+14%
|
1 779
+16%
|
1 508
-15%
|
1 037
-31%
|
735
-29%
|
|
| Operating Income | ||||||||||||
| Operating Expenses |
(286)
|
(286)
|
(315)
|
(365)
|
(424)
|
(548)
|
(597)
|
(701)
|
(805)
|
(715)
|
(666)
|
|
| Selling, General & Administrative |
(270)
|
(266)
|
(293)
|
(319)
|
(384)
|
(493)
|
(533)
|
(580)
|
(585)
|
(510)
|
(461)
|
|
| Research & Development |
(28)
|
(27)
|
(29)
|
(34)
|
(46)
|
(56)
|
(65)
|
(101)
|
(108)
|
(97)
|
(94)
|
|
| Depreciation & Amortization |
0
|
0
|
0
|
(25)
|
0
|
0
|
0
|
(29)
|
0
|
0
|
0
|
|
| Other Operating Expenses |
11
|
8
|
7
|
14
|
6
|
1
|
1
|
9
|
(112)
|
(108)
|
(112)
|
|
| Operating Income |
246
N/A
|
236
-4%
|
293
+24%
|
308
+5%
|
510
+65%
|
797
+56%
|
938
+18%
|
1 079
+15%
|
703
-35%
|
321
-54%
|
69
-78%
|
|
| Pre-Tax Income | ||||||||||||
| Interest Income Expense |
10
|
9
|
7
|
10
|
10
|
7
|
3
|
(4)
|
(10)
|
(11)
|
(8)
|
|
| Non-Reccuring Items |
0
|
1
|
1
|
1
|
1
|
1
|
0
|
(126)
|
(1)
|
(1)
|
1
|
|
| Gain/Loss on Disposition of Assets |
0
|
0
|
0
|
(1)
|
0
|
0
|
0
|
(1)
|
0
|
0
|
0
|
|
| Total Other Income |
(16)
|
(7)
|
(2)
|
0
|
(4)
|
(6)
|
(14)
|
(44)
|
(45)
|
(44)
|
(37)
|
|
| Pre-Tax Income |
240
N/A
|
239
0%
|
299
+25%
|
318
+7%
|
517
+63%
|
798
+54%
|
927
+16%
|
904
-2%
|
647
-28%
|
265
-59%
|
25
-91%
|
|
| Net Income | ||||||||||||
| Tax Provision |
(41)
|
(42)
|
(49)
|
(56)
|
(89)
|
(132)
|
(158)
|
(165)
|
(124)
|
(70)
|
(28)
|
|
| Income from Continuing Operations |
199
|
197
|
250
|
262
|
429
|
667
|
769
|
739
|
523
|
195
|
(3)
|
|
| Income to Minority Interest |
(35)
|
(35)
|
(55)
|
(58)
|
(101)
|
(130)
|
(139)
|
(122)
|
(62)
|
(10)
|
15
|
|
| Net Income (Common) |
146
N/A
|
144
-1%
|
177
+23%
|
204
+15%
|
328
+61%
|
536
+64%
|
631
+18%
|
617
-2%
|
461
-25%
|
185
-60%
|
12
-93%
|
|
| EPS (Diluted) |
0.36
N/A
|
0.35
-3%
|
0.44
+26%
|
0.58
+32%
|
0.83
+43%
|
1.35
+63%
|
1.58
+17%
|
1.54
-3%
|
1.15
-25%
|
0.46
-60%
|
0.03
-93%
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
